GlobeImmune, Inc.
OTC: GBIM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Donald Bellgrau
- Employees
- 2
- Headquarters
- Louisville, United States
- IPO year
- 2014
- Market cap
- $575.0
- Website
- https://www.globeimmune.com
Loading GBIM…
Loading profile data…Frequently asked questions about GBIM
What does GlobeImmune, Inc. (GBIM) do?
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline...
Where does GBIM trade?
GlobeImmune, Inc. (GBIM) trades on the Other OTC.
What sector is GBIM in?
GlobeImmune, Inc. (GBIM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GlobeImmune, Inc.?
Donald Bellgrau is the chief executive officer of GlobeImmune, Inc. (GBIM).
Where is GlobeImmune, Inc. headquartered?
GlobeImmune, Inc. is headquartered in United States.
Does GBIM pay a dividend?
GlobeImmune, Inc. (GBIM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GBIM go public?
GlobeImmune, Inc. (GBIM) completed its initial public offering in 2014.